Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 1.4. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||11%|
|1 Day Vol Adjusted Return||-0.5|
|1 Month Vol Adjusted Return||6.4|
|3 Month Vol Adjusted Return||19.0|
|6 Month Vol Adjusted Return|
|20 Days SMA Price ZScore||1.6|
|50 Days SMA Price ZScore||2.5|
|12 -26 Days PPO||23.2|
|1 Month Average Short Volume Ratio||44.2|
|1 Day Volume Change ZScore||-0.2|
|1 Month Daily Vol||21.6|
The recent IPO's coronavirus antibody breakthrough could be a game changer in the fight against COVID-19.
Shares of Immunome Inc. blasted 212.6% higher toward new highs Thursday, to pace all of the premarket gainers trading on major U.S. exchanges, after biopharmaceutical company said it has isolated potent antibodies that are capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351) in pseudovirus testing. Trading volume was about 506,600 shares, compared with the full-day average of about 117,600 shares. The company has been working to develop a cocktail of...
Immunome announces that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants
Immunome says it isolated antibodies that can blunt several COVID types, including the deadly South African mutant.
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, and Abzena, a partner research organization for integrated discovery to cGMP manufacturing solutions for biologics, today announced that Abzena was selected as Immunome’s partner research organization for IMM-BCP-01, an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target mult...
Immunome announces the release of findings from its ongoing preclinical COVID-19 research program
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Immunome appoints Richard Baron to BOD and Sandra Stoneman as Chief Legal Officer and Corporate Secretary